Información del artículo
Resumen
El incumplimiento del tratamiento farmacológico es considerada como una de las causas principales de la falta de control de la diabetes mellitus (DM). En España el incumplimiento del tratamiento antidiabético oral (ADO) ha sido analizado en varios estudios a corto plazo, habiéndose observado un incumplimiento entre el 45 y el 51,5%, mientras que el incumplimiento con insulina se ha analizado en un único estudio, donde se ha observado un incumplimiento del 25,2%. En el ámbito internacional, la magnitud del incumplimiento en la DM con ADO ronda entre el 6,7 y el 55%. El incumplimiento del tratamiento se ha asociado a un mal control de las cifras de glucemia y hemoglobina glucosilada, incremento de los costes sanitarios, mayor hospitalización y a una mayor morbimortalidad.
Palabras clave:
Atención primaria
Control: Cumplimiento terapéutico
Diabetes mellitus
Tratamiento farmacológico
Abstract
Therapeutic noncompliance is considered one of the main causes of the lack of control of diabetes mellitus (DM). In Spain, the oral antidiabetic (OAD) treatment noncompliance has been analyzed in several short-term studies, having been between 45% and 51.5%, while noncompliance with insulin was analyzed in a single study, where there has been a noncompliance of 25.2%. Internationally, the magnitude of noncompliance in DM with OAD is from 6.7 to 55%. Noncompliance was associated with poor control of blood glucose and glycosylated hemoglobin, increased health care costs, hospitalization, morbidity and mortality.
Keywords:
Primary Care
Control
Therapeutic compliance
Diabetes mellitus
Pharmacologic treatment
El Texto completo está disponible en PDF
Bibliografía
[1]
E. Márquez Contreras, J.J. Casado Martínez.
El incumplimiento farmacológico en las enfermedades cardiovasculares.
Med Clin, 116 (2001), pp. 54-56
[2]
E. Márquez Contreras, J.J. Casado Martínez, J.J. Márquez Cabeza.
Estrategias para mejorar el cumplimiento.
FMC, 8 (2001), pp. 558-573
[3]
J.A. Cramer, A. Benedict, N. Muszbek, A. Keskinaslan, Z.M. Khan.
The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.
Int J Clin Pract, 62 (2008), pp. 76-87
[4]
L.A. Donnelly, A.D. Morris, J.M. Evans, DARTS/MEMO collaboration.
Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.
QJM, 100 (2007), pp. 345-350
[5]
J.B. Brown, G.A. Nichol, H.S. Glauber, A. Bakst.
Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type-2 diabetes.
Clin Ther, 21 (1999), pp. 1045-1057
[6]
F. Piñeiro Chousa, V.F. Gil Guillén, M. Donis Otero, D. Orozco Beltrán, R. Pastor López, J. Merino Sánchez.
Validity of 6 indirect methods in the evaluation of compliance to drug treatment of non-insulin dependent diabetes mellitus.
Rev Clin Esp, 197 (1997), pp. 555-559
[7]
M.D. García Navarro, D. Orozco Beltrán, V. Gil Guillén, C. Carratalá Munuera, C. Terol Moltó, J. Merino Sánchez.
Relación entre cumplimiento farmacológico y grado de control en pacientes con hipertensión, diabetes o dislipemia.
Med Clin (Barc), 116 (2001), pp. 141-146
[8]
M.L. Gutiérrez-Angulo, P. Lopetegi-Uranga, I. Sánchez-Martín, M. Garaigordobil-Landazabal.
Cumplimiento terapéutico en pacientes con hipertensión arterial y diabetes mellitus.
Rev Calid Asist, 27 (2012), pp. 72-77
[9]
A. De León, J.C. Rodríguez, S.D. Coello, C. Pérez Mdel, B.B. Díaz, C.B. Alamo, et al.
Lifestyle and treatment adherence of type 2 diabetes mellitus people in the Canary Islands.
Rev Esp Salud Publica, 83 (2009), pp. 567-575
[10]
F. López-Simarro, C. Brotons, I. Moral, C. Cols-Sagarra, A. Selva, A. Aguado-Jodar, et al.
Inercia y cumplimiento terapéutico en pacientes con diabetes mellitus tipo 2 en atención primaria.
Med Clin (Barc), 138 (2012), pp. 377-384
[11]
E. Márquez Contreras, N. Martell Claros, V. Gil Guillén, J.J. Casado Martínez, J.L. Martín de Pablos, J. Ferraro García, et al.
Incumplimiento terapéutico con insulina en el tratamiento de la diabetes mellitus 2.
Aten Primaria, 44 (2012), pp. 74-81
[12]
J.F. Steiner, P.M. Ho, B.L. Beaty, L.M. Dickinson, R. Hanratty, C. Zeng, et al.
Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension.
Circ Cardiovasc Qual Outcomes, 2 (2009), pp. 451-457
[13]
J.A. Cramer.
A systematic review of adherence with medications for diabetes.
Diabetes Care, 27 (2004), pp. 1218-1224
[14]
M.I. Rosen, M.O. Rigsby, J.T. Salahi, C.E. Ryan, J.A. Cramer, S. Inzucchi.
Electronic monitoring and counseling to improve medication adherence.
Behav Res Ther, 42 (2004), pp. 409-422
[15]
W.C. Lee, S. Balu, D. Cobden, A.V. Joshi, C.L. Pashos.
Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review.
Manag Care Interface, 19 (2006), pp. 31-41
[16]
A.J. White, I. Kellar, A.T. Prevost, A.L. Kinmonth, S. Sutton, M. Canny, et al.
Adherence to hypoglycaemic medication among people with type 2 DM in primary care.
Prim Care Diabetes, 6 (2012), pp. 27-33
[17]
R. Rajagopalan, A. Joyce, D. Smith, D. Ollendorf, F.T. Murray.
Medication compliance in type 2 diabetes patients: retrospective data analysis [abstract].
Value Health, 6 (2003), pp. 328
[18]
R. Fabunmi, L.L. Nielsen, R. Quimbo, B. Schroeder, D. Misurski, M. Wintle, et al.
Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
Curr Med Res Opin, 25 (2009), pp. 777-786
[19]
V. Hutchins, B. Zhang, R.L. Fleurence, G. Krishnarajah, J. Graham.
A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes.
Curr Med Res Opin, 27 (2011), pp. 1157-1168
[20]
J.F. Scherrer, L.D. Garfield, P.J. Lustman, P.J. Hauptman, T. Chrusciel, A. Zeringue, et al.
Antidepressant drug compliance and diabetes: reduced risk of MI and mortality in depressed patients.
Am J Med, 124 (2011), pp. 318-324
[21]
I.S. Park.
Effect of medicine adherente on the ocurrente of cerebrovascular disorders in diabetes mellitus patients.
Epidemiol Health, 33 (2011), pp. 201-1001
[22]
P.M. Ho, J.S. Rumsfeld, F.A. Masoudi, D.L. McClure, M.E. Plomondon, J.F. Steiner, et al.
Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.
Arch Intern Med, 166 (2006), pp. 1836-1841
[23]
C. Asche, J. LaFleur, C. Conner.
A review of diabetes treatment adherence and the association with clinical and economic outcomes.
Clin Ther, 33 (2011), pp. 74-109
[24]
J.S. Hong, H.C. Kang.
Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea.
Med Care, 49 (2011), pp. 378-384
[25]
R.A. Hansen, J.F. Farley, M. Droege, M.L. Maciejewski.
A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005.
Clin Ther, 32 (2010), pp. 1308-1319
Copyright © 2012. Sociedad Española de Hipertension-Liga Española para la Lucha de la Hipertensión Arterial (SEH-LELHA)